Prurigo Nodularis
An Introduction to Prurigo nodularis
Prurigo nodularis (PN) is a chronic inflammatory skin disease with pruritic nodules. PN lesions may occur in any age group but are most commonly seen in older adults. It can be associated with another cutaneous hypersensitivity disorder, such as atopic dermatitis or chronic pruritus, and its exact aetiology remains poorly understood. The condition is associated with significant physical and psychological morbidity and is often refractory to treatment. With currently limited agents approved by the US Food and Drug Administration, the management of PN is difficult, and available treatment options are often multimodal due to the intersection of neuroimmune etiologic factors in the pathogenesis of PN. Novel therapies such as monoclonal antibodies, opioid-antagonists and interleukin-31 targeting agents are emerging, providing hope for this patient population.
Our supporting partners do not constitute an endorsement of the content on this page.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
The FDA has approved nemolizumab-ilto (Nemluvio; Galderma) for treating prurigo nodularis, a chronic skin condition characterized by intensely itchy nodules. Nemolizumab is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31, a neuroimmune cytokine that drives multiple disease mechanisms in prurigo nodularis
Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.
Select a discussion in our hub to watch our multidisciplinary experts, including a patient advocate, share important perspectives on the need to establish patient-centric treatment and care pathways for the management of prurigo nodularis.
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
